Cargando…
Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression
The hepatocyte-specific asialoglycoprotein receptor (ASGPR) is an ideal candidate for targeted drug delivery to the liver due to its high capacity for substrate clearance from circulation together with its well-conserved expression and function across species. The development of GalNAc-siRNA conjuga...
Autores principales: | Willoughby, Jennifer L.S., Chan, Amy, Sehgal, Alfica, Butler, James S., Nair, Jayaprakash K., Racie, Tim, Shulga-Morskaya, Svetlana, Nguyen, Tuyen, Qian, Kun, Yucius, Kristina, Charisse, Klaus, van Berkel, Theo J.C., Manoharan, Muthiah, Rajeev, Kallanthottathil G., Maier, Martin A., Jadhav, Vasant, Zimmermann, Tracy S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762979/ https://www.ncbi.nlm.nih.gov/pubmed/28988716 http://dx.doi.org/10.1016/j.ymthe.2017.08.019 |
Ejemplares similares
-
Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
por: Nair, Jayaprakash K., et al.
Publicado: (2017) -
Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
por: Brown, Christopher R, et al.
Publicado: (2020) -
Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
por: Foster, Donald J., et al.
Publicado: (2018) -
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
por: Janas, Maja M., et al.
Publicado: (2018) -
Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor
por: Schmidt, Karsten, et al.
Publicado: (2017)